AstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 Billion

Wall Street analysts expect that AstraZeneca plc (NYSE:AZN) will report sales of $5.76 billion for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for AstraZeneca’s earnings, with the lowest sales estimate coming in at $5.37 billion and the highest estimate coming in at $6.12 billion. AstraZeneca reported sales of $5.59 billion during the same quarter last year, which indicates a positive year over year growth rate of 3%. The firm is scheduled to issue its next earnings results on Thursday, February 1st.

According to Zacks, analysts expect that AstraZeneca will report full-year sales of $5.76 billion for the current fiscal year, with estimates ranging from $20.03 billion to $22.48 billion. For the next fiscal year, analysts anticipate that the business will report sales of $22.07 billion per share, with estimates ranging from $20.47 billion to $23.93 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover AstraZeneca.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.32 earnings per share.

A number of brokerages have weighed in on AZN. BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Leerink Swann boosted their price target on AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Citigroup raised AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Cowen reissued a “hold” rating and set a $37.00 price target on shares of AstraZeneca in a research report on Tuesday, October 17th. Finally, Credit Suisse Group raised AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $34.20.

Several institutional investors have recently bought and sold shares of the company. Fisher Asset Management LLC grew its position in shares of AstraZeneca by 4.7% in the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of AstraZeneca by 7.6% in the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after purchasing an additional 310,389 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of AstraZeneca by 7.1% in the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after purchasing an additional 199,519 shares during the last quarter. Capital Bank & Trust Co grew its position in shares of AstraZeneca by 2.1% in the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after purchasing an additional 57,353 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of AstraZeneca by 18.3% in the third quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock valued at $86,695,000 after purchasing an additional 395,699 shares during the last quarter. 14.75% of the stock is currently owned by institutional investors.

Shares of AstraZeneca (AZN) traded up $0.39 during midday trading on Thursday, reaching $34.11. The company’s stock had a trading volume of 2,441,142 shares, compared to its average volume of 2,640,000. The firm has a market capitalization of $84,690.00, a P/E ratio of 24.36, a PEG ratio of 3.06 and a beta of 0.76. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. AstraZeneca has a 1 year low of $26.51 and a 1 year high of $35.60.

COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 Billion” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2018/01/12/astrazeneca-plc-azn-expected-to-announce-quarterly-sales-of-5-76-billion.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply